Commission File Number: 001-35907 IQVIA HOLDINGS INC. ( All forward-looking statements are made only as of the date hereof. Most of this information is available on a subscription basis. With approximately 70,000 employees, we conduct operations in more than 100 countries. We are a global leader in protecting individual patient privacy. Increased Complexity in Research and Development. Need for demonstrated value in healthcare. We believe we are well positioned to take advantage of these global trends in healthcare. Analytics and consulting services. This will endure far beyond the crisis. Information on the SEC's website does not constitute part of this report. Additionally, we depend on third parties for support services to our business. As noted above, clinical trials can cost hundreds of millions of dollars. Cyber threats are rapidly evolving and are becoming increasingly sophisticated. These discussions may lead to further restrictions on the use of such information. The relationship of backlog to revenues varies over time. Once work begins on a project, revenue is recognized over the duration of the project. Also, increased IT-related expenditures may negatively impact our profitability. Significant technological change could render certain of our services obsolete. We face risks related to sales to government entities. We also compete with universities, teaching hospitals, governments agencies and others. If we do not compete successfully, our business will suffer. The biopharmaceutical industry is subject to rapid technological changes. Because we have variable rate debt, fluctuations in interest rates affect our business. In addition, IQVIA is subject to Section 203 of the DGCL regulating corporate takeovers. Item 1B. Unresolved Staff Comments None.39Item 2. In 2015, we wrote down $2 million related to long-lived assets. ( Site start-up activities continued to increase along with patient recruitment trends. The Company continues to maintain strong liquidity. Contracted backlog was $17.1 billion at December 31, 2018. Actual results may differ from those estimates. Significant judgment is required to evaluate assumptions related to these estimates. The determination of benefit obligations and expense is based on actuarial models. The principal currencies hedged in 2020 were the British Pound and the Japanese Yen. Cash flows are classified consistent with the underlying hedged item. Significant judgment is required to evaluate 70assumptions related to these estimates. Generally, the payment terms are 30 to 90 days based on contracts. The Company adopted this new accounting guidance on January 1, 2020. As of December 31, 2020, none 78of the 2015 Swaps were still outstanding. The critical terms of the swaps are substantially the same as the underlying borrowings. See Note 8 for additional information. On December 18, 2019, the Company entered into Amendment No. The following is a summary of certain legal matters involving the Company. The District Court did not award any damages to plaintiffs. IMS Korea and two of its employees were among the individuals and organizations indicted. No shares of preferred stock were issued and outstanding as of December 31, 2020 or 2019. Insurance contracts are valued at the amount of the benefit liability. Mr. Bruehlman has served as a director of The Connecticut Forum since 2005. Ltd.South AfricaIQVIA RDS Clindepharm (Pty.) SlovakiaIQVIA Technology Solutions s.r.o. "RM(8VDEFD8\\*B(K,3V -:%A?V.JV,.
